Stocks Making Moves: Hims & Hers, Vertex, Palantir, Darden and More

Business News

Stocks Making Moves: Hims & Hers, Vertex, Palantir, Darden and More
STOCK MARKETCOMPANY PERFORMANCEHEALTHCARE
  • 📰 CNBC
  • ⏱ Reading Time:
  • 35 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 34%
  • Publisher: 72%

A look at the companies seeing significant price changes in midday trading, including Hims & Hers, Vertex Pharmaceuticals, Palantir Technologies, Darden Restaurants, Accenture, and Micron Technology.

Hims & Hers shares dropped over 10% as the FDA declared the active ingredient in weight loss drugs Mounjaro and Zepbound is no longer in shortage. The company provides access to GLP-1 injections. Vertex Pharmaceuticals fell around 13% after announcing Phase 2 study results for suzetrigine, a pain signal inhibitor. While placebo recipients showed similar pain reduction, the company plans to proceed with Phase 3 trials. Palantir Technologies rose 4% following an extended partnership with the U.S.

Army, valued at $400.7 million for up to four years with a potential ceiling of $618.9 million. Darden Restaurants surged over 15% on better-than-expected same-store sales growth at Olive Garden and LongHorn Steakhouse. The company also increased its full-year revenue guidance to $12.1 billion. Accenture gained about 7% after exceeding fiscal first-quarter revenue expectations and raising its full-year guidance to 4% to 7% revenue growth. Finally, Micron Technology plummeted over 16% due to weaker-than-expected fiscal second-quarter guidance, attributed to weaker consumer-oriented markets. CEO Sanjay Mehrotra expects a return to growth in the second half of the fiscal year

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

STOCK MARKET COMPANY PERFORMANCE HEALTHCARE TECHNOLOGY RESTAURANTS

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Morgan Stanley Sees 53% Upside in Hims & Hers StockMorgan Stanley Sees 53% Upside in Hims & Hers StockAnalyst Craig Hettenbach initiated coverage of Hims & Hers Health with an overweight rating and $42 price target, citing strong growth prospects in mental health, weight loss, and dermatology treatments.
Read more »

Charts indicate this health-care stock could eventually double, according to Todd GordonCharts indicate this health-care stock could eventually double, according to Todd GordonThe chart analyst and investor breaks down the chart in Hims & Hers Health.
Read more »

Wall Street is turning bullish on this biotech. How to play it with optionsWall Street is turning bullish on this biotech. How to play it with optionsNishant Pant breaks down a bull call spread trade in Vertex Pharmaceuticals.
Read more »

Top 2025 Biotech Stocks to Watch Beyond Vaccine MakersTop 2025 Biotech Stocks to Watch Beyond Vaccine MakersStocks Analysis by MarketBeat.com (Nathan Reiff) covering: Eli Lilly and Company, Pfizer Inc, AstraZeneca PLC ADR, Hims Hers Health Inc. Read MarketBeat.com (Nathan Reiff)'s latest article on Investing.com
Read more »

Amazon Stock Eyes Growth With Bold Healthcare ExpansionAmazon Stock Eyes Growth With Bold Healthcare ExpansionStocks Analysis by MarketBeat.com (Jeffrey Neal Johnson) covering: Amazon.com Inc, Pharmocann Global Ltd, Hims Hers Health Inc. Read MarketBeat.com (Jeffrey Neal Johnson)'s latest article on Investing.com
Read more »

Here are Thursday's biggest analyst calls: Nvidia, Apple, Coca-Cola, McDonald's, Palantir & moreHere are Thursday's biggest analyst calls: Nvidia, Apple, Coca-Cola, McDonald's, Palantir & moreHere are Thursday's biggest calls on Wall Street.
Read more »



Render Time: 2025-02-14 19:38:43